Fevipiprant add-on therapy to reduce systemic corticosteroid use in severe asthma

Phase 3, randomised, double-blind trial in severe asthma comparing Fevipiprant plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Total systemic corticosteroid dose use. Started Sep 2018; status: terminated.